InVivo Therapeutics Announces Stanford Medicine as New Site for … – Business Wire (press release)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV)today announced that Stanford Medicine in Stanford, CA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Atman Desai, MD, has been named Principal Investigator at the site. Dr. Desai is a Director of Neurosurgical Spinal Oncology and Clinical Assistant Professor of Neurosurgery at Stanford University Medical Center.

Mark Perrin, InVivos CEO and Chairman, said, We are pleased to welcome one of the most recognized hospitals in the world to the INSPIRE Study. We look forward to working with Stanford Medicine and Dr. Desai, especially given Dr. Desais expertise in spinal cord injury treatment.

There are now 34 clinical sites participating in the clinical study:

For more information, please visit the companys ClinicalTrials.gov registration site: http://clinicaltrials.gov/ct2/show/study/NCT02138110.

About the Neuro-Spinal Scaffold ImplantFollowing acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural repair within and around the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in The INSPIRE Study for the treatment of patients with acute, complete (AIS A), thoracic traumatic spinal cord injury and a pilot study for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord injury. For more information on the cervical study, refer to https://clinicaltrials.gov/ct2/show/study/NCT03105882.

About InVivo TherapeuticsInVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Childrens Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the companys investigational Neuro-Spinal Scaffold received the 2015 Beckers Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit http://www.invivotherapeutics.com.

Excerpt from:
InVivo Therapeutics Announces Stanford Medicine as New Site for ... - Business Wire (press release)